naxitamab-gqgk

naxitamab-gqgk (DANYELZA) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

DANYELZA is a marketed brand name for naxitamab-gqgk. Check FDA Drugs@FDA for the current US label holder and prescribing information.

naxitamab-gqgk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.